A Phase 2, randomised, open label, multicentre study of an intraperitoneal a-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery

Oncoinvent AS0 个研究点目标入组 114 人开始时间: 2023年12月18日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Oncoinvent AS
入组人数: 114

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 65+（—）

入选标准

•Able and willing to provide written informed consent and to comply with the clinical study protocol (CSP)., Confirmed HR proficient by Myriad MyChoice CDx testing., Completed 3 or 4 cycles of NACT with regress or stable disease on diagnostic imaging and assessed to be operable to R0., Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 0 to 2 and patient fit enough to undergo IDS and further treatment according to standard of care., Adequate renal function: Calculated creatinine clearance using the Cockcroft-Gault formula = 40 ml/min or measured creatinine clearance = 40 ml/min., Adequate hepatic function: 1) Serum bilirubin < 1.5 x upper limit of normal (ULN), and 2) Aspartate transaminase and alanine transaminase = 3 x ULN., Adequate bone marrow function: 1) Absolute neutrophil count = 1.0 x 10^9/l, and 2) Platelets = 100 x 10^9/l, and 3) Haemoglobin = 9 g/dL., For females of childbearing potential, a negative pregnancy test must be documented prior to enrolment., For females of childbearing potential agreement to use at least one of the following highly effective (failure rate < 1%) methods of contraception during the treatment period and for at least 9 months if they receive Radspherin®, unless hysterectomy or oophorectomy is performed during IDS. 1) Total abstinence (when this is in line with the preferred and usual lifestyle of the patient), periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 2) Female sterilisation (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before enrolment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment. 3) Use of oral (oestrogen and progesterone), injected or implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system, or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception. In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Note: In addition to the use of one highly effective method of contraception as listed above, a condom is required for all male partners during the treatment period and for at least 9 months after the dose of IMP, unless vasectomised at least 6 months prior to enrolment., Female of age = 18 years., Patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (FIGO Stage IIIB/C or IV)., Peritoneal and other metastases eligible for IDS to no residual tumour., Adverse events recovered to at least Grade 1 from the effects (excluding alopecia) of any prior medical therapy for malignancy.

排除标准

•Known somatic or germline BRCA1 or BRCA2 mutations or confirmed HR deficient., Active liver disease with positive serology for active hepatitis B, hepatitis C or known human immunodeficiency virus (HIV)., Concurrent congestive heart failure or prior history of New York Heart Association (NYHA) class III/IV cardiac disease., Any condition or illness that, in the opinion of the investigator or the medical monitor, would compromise the safety of the patients or interfere with the evaluation of the safety of the investigational medicinal product., In the investigator’s opinion not able to comply with study procedures. Any medical or psychological condition that would preclude participation in the study or compromise the ability to give informed consent., Administration of an investigational medicinal product within 4 weeks, or at least 5 times the half-life, prior to enrolment., Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to, and up to 4 weeks after the surgery., Treatment with bevacizumab within 5 weeks prior to IDS., Known hypersensitivity to any of the excipients of the study drug., Suspicion of peritoneal leak, shunt, or otherwise suspected atypical target compartment pharmacokinetics, based on investigator’s judgement, patient history and diagnostic images., Epithelial borderline tumours, ovarian clear cell carcinoma, mucinous ovarian carcinoma, malignant Brenner tumours, non-epithelial ovarian malignancies, carcinosarcoma and neuroendocrine tumours or recurrent ovarian cancer., Symptomatic central nervous system metastasis., Another primary malignancy within the past 3 years (except for non-melanoma skin cancer, cutaneous melanoma stage 1, cervical cancer in situ or FIGO 2023 Stage IA1 or IA3 prior or synchronous endometrial cancer)., Prior abdominal/pelvic radiotherapy., Disease progression during 3 to 4 cycles of NACT., Pregnant or lactating (nursing) women., Active infections requiring antibiotics, and/or physician monitoring, or recurrent fever > 38.0 °C associated with a clinical diagnosis of active infection.

研究者

发起方

Oncoinvent AS

相似试验

进行中（未招募）

1 期

Phase 2 randomised study of Radspherin® in patients with peritoneal carcinomatosis from colorectal carcinoma after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)Carcinomatosis of peritoneal cavityMedDRA version: 20.0Level: LLTClassification code: 10068069Term: Peritoneal carcinomatosis Class: 10029104

CTIS2023-508496-37-00Oncoinvent AS102

招募中

2 期

A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated MyelofibrosisMyelofibrosis

2024-513605-31-00Karyopharm Therapeutics Inc.28

进行中（未招募）

1 期

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated MyelofibrosisMyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-003809-60-HUKaryopharm Therapeutics Inc.112

进行中（未招募）

1 期

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated MyelofibrosisMedDRA version: 20.0Level: PTClassification code 10028537Term: MyelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074689Term: Post polycythemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10074690Term: Post essential thrombocythemia myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10074691Term: Post polycythaemia vera myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10077161Term: Primary myelofibrosisSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Myelofibrosis

EUCTR2020-003809-60-PLKaryopharm Therapeutics Inc.112

进行中（未招募）

1 期

EUCTR2020-003809-60-GRKaryopharm Therapeutics Inc.112